The therapeutic potential of GPR119 agonists for type 2 diabetes.
about
Cyclic AMP dynamics in the pancreatic β-cellGut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studiesAngelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivoDiscovery of DS-1558: A Potent and Orally Bioavailable GPR40 AgonistAdenylyl Cyclase Type 5 Deficiency Protects Against Diet-Induced Obesity and Insulin ResistanceConstitutive Activity among Orphan Class-A G Protein Coupled ReceptorsEndocannabinoids--at the crossroads between the gut microbiota and host metabolism.Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents.A novel insulinotropic mechanism of whole grain-derived γ-oryzanol via the suppression of local dopamine D2 receptor signalling in mouse isletChemical methods to induce Beta-cell proliferation.Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells.Intercellular Lipid Mediators and GPCR Drug DiscoveryA lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasisIs GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis.Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.
P2860
Q27008275-58B443A4-AB63-444A-A6AC-D119F035CC91Q28541879-D2A3861C-F9E1-4A63-BCE1-850BE2460B80Q28552543-BDF5C10F-561C-4384-8F8D-37CBE6B86FB1Q30582571-6CE2FBDC-D672-4BF2-BDEE-2D7F106F50C7Q33849176-C67CB0CB-711C-4E1F-878F-4183A642FC64Q35178871-B696BC1D-D2B4-4DA9-B1D8-7BB8C325EC80Q35769605-B97A8CB5-3D36-41A8-8265-B33050963CF2Q35780544-A07A979D-85CB-472A-BAFD-C9651FBBA0BAQ35871872-F35D1835-5C59-4606-862C-4A67D62E517DQ35882718-DC40EC4A-40F9-4F6A-8DF7-CC5161685F52Q36036244-CD722F63-31DB-43FB-B221-19292FD59D7CQ36090704-68D703AB-9806-4E86-A423-02129DAD31CEQ36677839-1E8A3800-7F92-4740-A13C-A7C21140BC3AQ37429742-C4F99BD4-465B-4AD4-972F-376225045ACFQ37665457-A64BD705-7136-403F-9FEF-4656C9F1FD96Q38084735-34DD8629-F920-467A-95A9-2410E4C196E1Q38313784-44FEB5D6-FDFC-4F72-96D0-6150BB3969C2Q38688833-68190035-EE7E-4A2A-8C20-D2DA816895FEQ39145769-F3E31113-795B-4844-A09B-E1674196DACDQ39775206-AF715839-6FC5-481A-A91F-E2AB8566456EQ41982670-63749CFD-9A72-4E17-95FD-8150B60FBA52
P2860
The therapeutic potential of GPR119 agonists for type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The therapeutic potential of GPR119 agonists for type 2 diabetes.
@en
The therapeutic potential of GPR119 agonists for type 2 diabetes.
@nl
type
label
The therapeutic potential of GPR119 agonists for type 2 diabetes.
@en
The therapeutic potential of GPR119 agonists for type 2 diabetes.
@nl
prefLabel
The therapeutic potential of GPR119 agonists for type 2 diabetes.
@en
The therapeutic potential of GPR119 agonists for type 2 diabetes.
@nl
P2860
P1476
The therapeutic potential of GPR119 agonists for type 2 diabetes.
@en
P2093
Shigeru Yoshida
Takahide Ohishi
P2860
P304
P356
10.1517/13543784.2012.657797
P407
P577
2012-02-03T00:00:00Z